Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 3
2017 2
2018 1
2019 5
2020 1
2021 5
2022 6
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events.
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G, Escors D. Les I, et al. Among authors: arrazubi v. Cancers (Basel). 2023 Mar 6;15(5):1629. doi: 10.3390/cancers15051629. Cancers (Basel). 2023. PMID: 36900420 Free PMC article. Review.
Omics Approaches in Pancreatic Adenocarcinoma.
González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. González-Borja I, et al. Among authors: arrazubi v. Cancers (Basel). 2019 Jul 25;11(8):1052. doi: 10.3390/cancers11081052. Cancers (Basel). 2019. PMID: 31349663 Free PMC article. Review.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
State of the Art: ctDNA in Upper Gastrointestinal Malignancies.
Labiano I, Huerta AE, Arrazubi V, Hernandez-Garcia I, Mata E, Gomez D, Arasanz H, Vera R, Alsina M. Labiano I, et al. Among authors: arrazubi v. Cancers (Basel). 2023 Feb 21;15(5):1379. doi: 10.3390/cancers15051379. Cancers (Basel). 2023. PMID: 36900172 Free PMC article. Review.
Treatment in esophagogastric junction cancer: Past, present and future.
Pericay C, Macías-Declara I, Arrazubi V, Vilà L, Marín M. Pericay C, et al. Among authors: arrazubi v. Cir Esp (Engl Ed). 2019 Oct;97(8):459-464. doi: 10.1016/j.ciresp.2019.03.016. Epub 2019 May 31. Cir Esp (Engl Ed). 2019. PMID: 31155142 Review. English, Spanish.
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R. Rueda Domínguez A, et al. Among authors: arrazubi v. Clin Transl Oncol. 2022 Apr;24(4):670-680. doi: 10.1007/s12094-022-02814-x. Epub 2022 Mar 18. Clin Transl Oncol. 2022. PMID: 35303267 Free PMC article.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macía-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernández Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limón ML, Pimentel P, Martínez Lago N, Sauri T, Martín Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martín Carnicero A, Hernández Pérez C, Cerdá P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martín M, Weaver J, Mansoor W, Gallego J. Jimenez-Fonseca P, et al. Among authors: arrazubi v. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895850 Free PMC article.
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
González-Borja I, Alors-Pérez E, Amat I, Alonso L, Viyuela-García C, Goñi S, Reyes JC, Ceballos-Chávez M, Hernández-García I, Sánchez-Frías ME, Santamaría E, Razquin S, Arjona-Sánchez Á, Arrazubi V, Pérez-Sanz J, Vera R, Fernández-Irigoyen J, Castaño JP, Viúdez A. González-Borja I, et al. Among authors: arrazubi v. Front Med (Lausanne). 2021 Nov 19;8:720128. doi: 10.3389/fmed.2021.720128. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34869418 Free PMC article.
31 results